Exendin-4 ameliorates traumatic brain injury-induced cognitive impairment in rats

Katharine Eakin, Yazhou Li, Yung Hsiao Chiang, Barry J. Hoffer, Hilary Rosenheim, Nigel H. Greig, Jonathan P. Miller

Research output: Contribution to journalArticle

35 Citations (Scopus)

Abstract

Traumatic brain injury represents a major public health issue that affects 1.7 million Americans each year and is a primary contributing factor (30.5%) of all injury-related deaths in the United States. The occurrence of traumatic brain injury is likely underestimated and thus has been termed "a silent epidemic". Exendin-4 is a long-acting glucagon-like peptide-1 receptor agonist approved for the treatment of type 2 diabetes mellitus that not only effectively induces glucose-dependent insulin secretion to regulate blood glucose levels but also reduces apoptotic cell death of pancreatic β-cells. Accumulating evidence also supports a neurotrophic and neuroprotective role of glucagon-like peptide-1 in an array of cellular and animal neurodegeneration models. In this study, we evaluated the neuroprotective effects of Exendin-4 using a glutamate toxicity model in vitro and fluid percussion injury in vivo. We found neuroprotective effects of Exendin-4 both in vitro, using markers of cell death, and in vivo, using markers of cognitive function, as assessed by Morris Water Maze. In combination with the reported benefits of ex-4 in other TBI models, these data support repositioning of Exendin-4 as a potential treatment for traumatic brain injury.

Original languageEnglish
Article numbere82016
JournalPLoS One
Volume8
Issue number12
DOIs
Publication statusPublished - Dec 2 2013

Fingerprint

Rats
Brain
neuroprotective effect
brain
cell death
rats
Neuroprotective Agents
Cell death
glucagon-like peptide 1
Cell Death
insulin secretion
Percussion
noninsulin-dependent diabetes mellitus
cognition
glutamates
blood glucose
agonists
Glucagon-Like Peptide 1
public health
Wounds and Injuries

ASJC Scopus subject areas

  • Agricultural and Biological Sciences(all)
  • Biochemistry, Genetics and Molecular Biology(all)
  • Medicine(all)

Cite this

Eakin, K., Li, Y., Chiang, Y. H., Hoffer, B. J., Rosenheim, H., Greig, N. H., & Miller, J. P. (2013). Exendin-4 ameliorates traumatic brain injury-induced cognitive impairment in rats. PLoS One, 8(12), [e82016]. https://doi.org/10.1371/journal.pone.0082016

Exendin-4 ameliorates traumatic brain injury-induced cognitive impairment in rats. / Eakin, Katharine; Li, Yazhou; Chiang, Yung Hsiao; Hoffer, Barry J.; Rosenheim, Hilary; Greig, Nigel H.; Miller, Jonathan P.

In: PLoS One, Vol. 8, No. 12, e82016, 02.12.2013.

Research output: Contribution to journalArticle

Eakin, K, Li, Y, Chiang, YH, Hoffer, BJ, Rosenheim, H, Greig, NH & Miller, JP 2013, 'Exendin-4 ameliorates traumatic brain injury-induced cognitive impairment in rats', PLoS One, vol. 8, no. 12, e82016. https://doi.org/10.1371/journal.pone.0082016
Eakin, Katharine ; Li, Yazhou ; Chiang, Yung Hsiao ; Hoffer, Barry J. ; Rosenheim, Hilary ; Greig, Nigel H. ; Miller, Jonathan P. / Exendin-4 ameliorates traumatic brain injury-induced cognitive impairment in rats. In: PLoS One. 2013 ; Vol. 8, No. 12.
@article{fbeec631d995468e88afbbba815e7f72,
title = "Exendin-4 ameliorates traumatic brain injury-induced cognitive impairment in rats",
abstract = "Traumatic brain injury represents a major public health issue that affects 1.7 million Americans each year and is a primary contributing factor (30.5{\%}) of all injury-related deaths in the United States. The occurrence of traumatic brain injury is likely underestimated and thus has been termed {"}a silent epidemic{"}. Exendin-4 is a long-acting glucagon-like peptide-1 receptor agonist approved for the treatment of type 2 diabetes mellitus that not only effectively induces glucose-dependent insulin secretion to regulate blood glucose levels but also reduces apoptotic cell death of pancreatic β-cells. Accumulating evidence also supports a neurotrophic and neuroprotective role of glucagon-like peptide-1 in an array of cellular and animal neurodegeneration models. In this study, we evaluated the neuroprotective effects of Exendin-4 using a glutamate toxicity model in vitro and fluid percussion injury in vivo. We found neuroprotective effects of Exendin-4 both in vitro, using markers of cell death, and in vivo, using markers of cognitive function, as assessed by Morris Water Maze. In combination with the reported benefits of ex-4 in other TBI models, these data support repositioning of Exendin-4 as a potential treatment for traumatic brain injury.",
author = "Katharine Eakin and Yazhou Li and Chiang, {Yung Hsiao} and Hoffer, {Barry J.} and Hilary Rosenheim and Greig, {Nigel H.} and Miller, {Jonathan P.}",
year = "2013",
month = "12",
day = "2",
doi = "10.1371/journal.pone.0082016",
language = "English",
volume = "8",
journal = "PLoS One",
issn = "1932-6203",
publisher = "Public Library of Science",
number = "12",

}

TY - JOUR

T1 - Exendin-4 ameliorates traumatic brain injury-induced cognitive impairment in rats

AU - Eakin, Katharine

AU - Li, Yazhou

AU - Chiang, Yung Hsiao

AU - Hoffer, Barry J.

AU - Rosenheim, Hilary

AU - Greig, Nigel H.

AU - Miller, Jonathan P.

PY - 2013/12/2

Y1 - 2013/12/2

N2 - Traumatic brain injury represents a major public health issue that affects 1.7 million Americans each year and is a primary contributing factor (30.5%) of all injury-related deaths in the United States. The occurrence of traumatic brain injury is likely underestimated and thus has been termed "a silent epidemic". Exendin-4 is a long-acting glucagon-like peptide-1 receptor agonist approved for the treatment of type 2 diabetes mellitus that not only effectively induces glucose-dependent insulin secretion to regulate blood glucose levels but also reduces apoptotic cell death of pancreatic β-cells. Accumulating evidence also supports a neurotrophic and neuroprotective role of glucagon-like peptide-1 in an array of cellular and animal neurodegeneration models. In this study, we evaluated the neuroprotective effects of Exendin-4 using a glutamate toxicity model in vitro and fluid percussion injury in vivo. We found neuroprotective effects of Exendin-4 both in vitro, using markers of cell death, and in vivo, using markers of cognitive function, as assessed by Morris Water Maze. In combination with the reported benefits of ex-4 in other TBI models, these data support repositioning of Exendin-4 as a potential treatment for traumatic brain injury.

AB - Traumatic brain injury represents a major public health issue that affects 1.7 million Americans each year and is a primary contributing factor (30.5%) of all injury-related deaths in the United States. The occurrence of traumatic brain injury is likely underestimated and thus has been termed "a silent epidemic". Exendin-4 is a long-acting glucagon-like peptide-1 receptor agonist approved for the treatment of type 2 diabetes mellitus that not only effectively induces glucose-dependent insulin secretion to regulate blood glucose levels but also reduces apoptotic cell death of pancreatic β-cells. Accumulating evidence also supports a neurotrophic and neuroprotective role of glucagon-like peptide-1 in an array of cellular and animal neurodegeneration models. In this study, we evaluated the neuroprotective effects of Exendin-4 using a glutamate toxicity model in vitro and fluid percussion injury in vivo. We found neuroprotective effects of Exendin-4 both in vitro, using markers of cell death, and in vivo, using markers of cognitive function, as assessed by Morris Water Maze. In combination with the reported benefits of ex-4 in other TBI models, these data support repositioning of Exendin-4 as a potential treatment for traumatic brain injury.

UR - http://www.scopus.com/inward/record.url?scp=84891464127&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84891464127&partnerID=8YFLogxK

U2 - 10.1371/journal.pone.0082016

DO - 10.1371/journal.pone.0082016

M3 - Article

VL - 8

JO - PLoS One

JF - PLoS One

SN - 1932-6203

IS - 12

M1 - e82016

ER -